Arcus Biosciences Inc. Stock News

Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.

The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St

Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer dr

Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that

The consensus price target hints at a 44.5% upside potential for Arcus Biosciences, Inc. (RCUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gilead's Cancer Program Notches Another Wi

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 14.29% and 83.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people

Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Acquires Biohaven For $11B Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -215.66% and 88.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto

Travere (TVTX) delivered earnings and revenue surprises of -41.18% and 8.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?